{"nctId":"NCT00377819","briefTitle":"Study of Transitioning From Alendronate to Denosumab","startDateStruct":{"date":"2006-09"},"conditions":["Postmenopausal Osteoporosis"],"count":504,"armGroups":[{"label":"denosumab","type":"EXPERIMENTAL","interventionNames":["Drug: Denosumab (AMG 162)"]},{"label":"alendronate","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: alendronate"]}],"interventions":[{"name":"alendronate","otherNames":[]},{"name":"Denosumab (AMG 162)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Postmenopausal females 55 yrs or older\n* Received alendronate therapy for osteoporosis for at least 6 months prior to entry into study\n* Lumbar spine or total hip Bone Mineral Density (BMD) corresponding to T-score ≤ -2 and ≥ -4\n\nExclusion Criteria:\n\n* Vitamin D deficiency\n* Administration of intravenous bisphosphonate, or\n* fluoride (except for dental treatment) or\n* strontium ranelate\n* Administration of Parathyroid Hormone (PTH) or Parathyroid Hormone (PTH) derivatives (eg; teriparatide) within the last year\n* Administration of any bisphosphonate other than alendronate (ALN) within 1 year of screening","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"55 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Total Hip Bone Mineral Density","description":"Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change calculated using \\[(12 month value - baseline value) / baseline value\\]\\*100.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.05","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lumbar Spine Bone Mineral Density","description":"Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change calculated using \\[(12 month value - baseline value) / baseline value\\]\\*100.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.85","spread":null},{"groupId":"OG001","value":"3.03","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Serum C-Telopeptide-I (CTX-I)","description":"Percent Change From Baseline to Month 3 in Serum CTX-I. Percent change calculated using \\[(3 month value - baseline value) / baseline value\\]\\*100.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.2","spread":null},{"groupId":"OG001","value":"-63.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":16,"n":249},"commonTop":["Nasopharyngitis","Back pain","Arthralgia","Pain in extremity","Bronchitis"]}}}